Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Glucosamine

Summary

Persistence. It cannot be excluded that glucosamine is persistent, due to the lack of data.

Bioaccumulation. It cannot be excluded that glucosamine bioaccumulates, due to the lack of data.

Toxicity. It cannot be excluded that glucosamine is toxic, due to the lack of data.

Risk. Risk of environmental impact of glucosamine cannot be excluded, due to the lack of environmental toxicity data.

 

This summary information comes from Artrox (glucosamine) from Fass.se.

Detailed information

Comment on Fass environmental information

Glucosamine has different classifications on fass.se. According to Lif (the trade association for the research-based pharmaceutical industry in Sweden) the various pharmaceutical companies compile environmental information for their active substances based on internal studies and published data. Based on data, which may thus differ between different pharmaceutical companies, the companies assess the environmental risk with guidance from “Environmental classification of pharmaceuticals at www.fass.se – Guidance for pharmaceutical companies 2012”. The Swedish Environmental Institute (IVL) reviews the assessment but does not have the task of coordinating/harmonizing environmental information from different pharmaceutical companies for the same active substance.

Fass environmental information for Artrox

Fass environmental information for Artrox (glucosamine) from Pfizer (downloaded 2022-11-29).

Hazard

Persistence: No data.

Bioaccumulation: No data. 

Toxicity: No data.

Risk

Risk of environmental impact of glucosamine cannot be excluded, due to the lack of environmental toxicity data.

Fass environmental information for Glukosamin Pharma Nord

Fass environmental information for Glukosamin Pharma Nord (glucosamine) from Pharma Hus (downloaded 2022-11-29).

Risk

The use of carbohydrates is not considered to cause any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00),vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

Author: Health and Medical Care Administration, Region Stockholm